logo

For the Inventor, By the Inventor

Waltham, MA, United States of America

Regenacy Pharmaceuticals, LLC


USPTO Granted Patents = 16

% Expired Patents = 37.5


Forward Citations = 25

Loading Chart...
Loading Chart...

8 inventors (with patents filed for the assignee):

goldMedal Ralph Mazitschek (12 out of 63 patents)

silverMedal John Henry Van Duzer (12 out of 55 patents)

bronzeMedal Matthew B Jarpe (4 out of 5 patents)

4.  Annemieke Kavelaars (2 out of 3 patents)

5.  Cobi J Heijnen (2 out of 3 patents)

6.  Karen Krukowski (2 out of 2 patents)

7.  Olga Golonzhka (2 out of 2 patents)

8.  Charles Blum (1 out of 1 patent)


16 patents:

1. 11858919 - HDAC1,2 inhibitors (2024-01-02),
2. 11702389 - Piperidine derivatives as HDAC1/2 inhibitors (2023-07-18),
3. 11542242 - Substituted piperazines as selective HDAC1,2 inhibitors (2023-01-03),
4. 11013740 - Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy (2021-05-25),
5. 10968180 - Piperidine derivatives as HDAC1/2 inhibitors (2021-04-06),
6. 10858323 - HDAC inhibitors for the treatment of diabetic peripheral neuropathy (2020-12-08),
7. 10774056 - Substituted piperazines as selective HDAC1,2 inhibitors (2020-09-15),
8. 10385031 - Substituted piperazines as selective HDAC1,2 inhibitors (2019-08-20),
9. 10358421 - Piperidine derivatives as HDAC1/2 inhibitors (2019-07-23),
10. 10272084 - Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy (2019-04-30),
11. 10239837 - Piperidine derivatives as HDAC1/2 inhibitors (2019-03-26),
12. 10125131 - Selective HDAC3 inhibitors (2018-11-13),
13. 10040769 - HDAC inhibitors for the treatment of diabetic peripheral neuropathy (2018-08-07),
14. 9957259 - Selective HDAC1 and HDAC2 inhibitors (2018-05-01),
15. 9790180 - Piperidine derivatives as HDAC1/2 inhibitors (2017-10-17),
Regenacy Pharmaceuticals, LLC is a biopharmaceutical company based in Waltham, MA, focused on developing innovative therapies for patients with serious diseases. The company specializes in advancing treatments that target unmet medical needs, particularly in the areas of neurology and metabolic disorders. By leveraging cutting-edge research and technology, Regenacy aims to improve patient outcomes and enhance the quality of life for individuals affected by these conditions.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Regenacy Pharmaceuticals, LLC
16 Patents

#90 in Waltham, MA

#1,202 in Massachusetts

#19,907 in US

#37,788 in the World

Waltham, MA (US)
Waltham, MA, United States of America

Regenacy Pharmaceuticals, LLC

Forward Citations = 25

8 inventors:

goldMedal Ralph Mazitschek (12 out of 63 patents)

silverMedal John Henry Van Duzer (12 out of 55 patents)

bronzeMedal Matthew B Jarpe (4 out of 5 patents)

4.  Annemieke Kavelaars (2 out of 3 patents)

5.  Cobi J Heijnen (2 out of 3 patents)

Please report any incorrect information to [email protected]
Loading…